A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations

Year 2017, Volume: 34 Issue: 1, 1 - 9, 01.01.2017

Erden Atilla Pınar Ataca Atilla Taner Demirer

Abstract

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic transplantation: Myeloablative (MA), Reduced Intensity Conditioning (RIC) and Non-MA (NMA) regimens. MA regimens cause irreversible cytopenia and there is a requirement for stem cell support. Patients who receive NMA regimen have minimal cytopenia and this type of regimen can be given without stem cell support. RIC regimens do not fit the criteria of MA and NMA: the cytopenia is reversible and the stem cell support is necessary. NMA/RIC for Allo-HSCT has opened a new era for treating elderly patients and those with comorbidities. The RIC conditioning was used for 40% of all Allo-HSCT and this trend continue to increase. In this paper, we will review these regimens in the setting of especially allogeneic HSCT and our aim is to describe the history, features and impact of these conditioning regimens on specific diseases.

Keywords

Conditioning regimens, myeloablative, nonmyeloablative, reduced-intensity

References

• 1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions.Biol Blood Marrow Transplant 2009;15:1628-33.
• 2. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P, et al. The EBMT activity survey:1990-2010. Bone Marrow Transplant 2012;47:906-23.
• 3. Demirer T, Buckner CD, Appelbaum FR, Besinger WI, Sanders J, Lambert K, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996;17:491- 5.
• 4. Demirer T, Buckner CD, Appelbaum FR, Lambert K, Besinger WI, Clift R, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996;17:341- 6.
• 5. De Giorgi U, Rosti G, Slavin S, Yaniv I, Harousseau JL, Ladenstein R, et al. Salvage high-dose chemotherapy for children with extragonadal germcell tumours. Br J Cancer 2005;93:412-7.
• 6. Pedrazzoli P, Ledermann JA, Lotz JP, Leyvraz S, Aglietta M, Rosti G, et al. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Ann Oncol 2006;17:1479-88.
• 7. Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel, Castel V, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008;41(Suppl 2):118-27.
• 8. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleby K, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996;18:527-31.
• 9. Demirer T, Petersen FB, Bensinger WI, Appelbaum FR, Fafer A, Rowley S, et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplant 1996;18:29-34.
• 10. Demirer T, Celebi H, Arat M, Ustun C, Demirer S, Dilek I, et al. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;24:335-7.
• 11. Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, et al. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant 2003;32:1153-7.
• 12. Pedrazzoli P, Ferrante P, Kulekci A, Schiavo R, De Giorgi U, Carminati O, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant 2003;32:489-94.
• 13. Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplant 1995;15:907-13.
• 14. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials . J Clin Oncol 2011;29:3224-31.
• 15. De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, et al. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol 2005;16:146-51.
• 16. Brunvand MW, Bensinger WI, Soll E, Weaver CH, Rowley SD, Appelbaum FR, et al. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. Bone Marrow Transplant 1996;18:131-41.
• 17. Demirer T, Buckner CD, Appelbaum FR, Clift R, Storb R, Myerson D, et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996;17:769-74.
• 18. Thomas’ Hematopoietic Cell Transplantation Third Edition- Edited By Blume KG, Forman SJ, Appelbaum FR, 2004, Chapter 13 Preparative Regimens and Modification of Regimen-Related Toxicities, Bensinger WI, Spielberger R.
• 19. Lorenz E, Uphoff D, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197-201.
• 20. Bortin MM. A compendium of reported human bone marrow transplants. Transplantation 1970;9:571-87.
• 21. Epstein RB, Storb R, Ragde H, Thomas ED. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation 1968;6:45-58.
• 22. Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970;9:240-6.
• 23. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895-902.
• 24. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-53.
• 25. Molina AJ, Storb RF. Hematopoietic stem cell transplantation in older adults. In: Rowe LM, Lazarus HM, Carella AM, editors. Handbook of bone marrow transplantation. London: Martin Dunitz; 2000:111-37.
• 26. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004;26:71-94.
• 27. Peccatori J, Barkholt L, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005;104:2099-103.
• 28. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkiel G, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol 2006;17:1134-40.
• 29. Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F, et al. Reducued intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica 2007;92:418-20.
• 30. Aglietta M, Barkholt L, Schianca FC, Caravelli D, Omazic B, Minotto C, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. Biology Blood Marrow Transplant 2009;15:326-35.
• 31. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008;5:256-67.
• 32. Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M; EBMT STWP. Is adoptive T-cell therapy for solid tumors coming of age? Bone Marrow Transplant 2012;47:1013-9.
• 33. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone-marrow transplantation. Blood 1990;75:555-62.
• 34. Baron F, Petersdorf EW, Gooley T, Sandmaier BM, Malkki M, Chauncey TR, et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009;15:580-8.
• 35. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus- host disease and disease remission. Blood 2005;105:2973-8.
• 36. European group for Blood and Marrow Transplantation (EBMT) Handbook 6th edition, Chapter 8. Principals of conditioning. Editors J.Apperley, E. Carreras, E. Gluckman, T. Masszi, 2012.
• 37. Servais S, Baron F, Beguin Y. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfus Apher Sci 2011;205-10.
• 38. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254-62.
• 39. Mohty M, Labopin M, Janssen JJWM, Mufti GJ, Cornelissen JJ, Milpied NJ, et al. Comparison of low dose total body irradiation (TBI)-based reduced intensity conditioning (RIC) vs. chemotherapy-based RIC prior to allogeneic stem cell transplantation (allo-SCT) from an HLA identical sibling donor for Acute Myeloid Leukemia (AML) in first complete remission (CR1): a retrospective analysis of 1200 Patients from the Acute Leukemia Working Party of EBMT. Blood 2009;114:1190.
• 40. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993-2003.
• 41. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
• 42. Larosa F, Marmier C, Robinet E, Ferrand C, Saas P, Deconinck E, et al. Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation. Bone Marrow Transplant 2005;35:859-68.
• 43. Kim SH, Kee SY, Lee DG, Choi SM, Park SH, Kwon JC, et al. Infectious complications following stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens. Transpl Infect Dis 2013:15:49-59.
• 44. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304-12.
• 45. Jimenez M, Ercilla G, Martinez C. Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia 2007;21:1628-37.